

Supporting Information

The Chiron Approach to (3*R*,3*aS*,6*aR*)-hexahydrofuro[2,3-*b*]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir


Arun K. Ghosh,* Shivaji B. Markad, and William L. Robinson

*Department of Chemistry and Department of Medicinal Chemistry, Purdue University, 560 Oval
Drive, West Lafayette, Indiana 47907*

akghosh@purdue.edu

Contents:

¹ H-NMR and ¹³ C-NMR Spectra.....	S2-S31
Zoomed NMR Spectra.....	S32-S48
HPLC Data.....	S49-S52



167.28

133.47
129.80
129.13
128.40

111.76


104.64

84.93


78.43
77.26
76.94
76.62
74.30


61.24

26.69
26.05





¹³C-NMR (100 MHz, CDCl₃)







¹H-NMR (400 MHz, CDCl₃)







$^{13}\text{C-NMR}$ (100 MHz, CDCl_3)













$^{13}\text{C-NMR}$ (100 MHz, CDCl_3)














































S21














S25



















S31










































¹H-NMR (400 MHz, CDCl₃)










¹H-NMR (400 MHz, CDCl₃)








Additional Info : Peak(s) manually integrated



Sample Info : 50% IPA/hexanes
 CHIRALPAK OD-H
 0.3 mL/min
 254 nm
 5 uL inj.
 0.633 mg/mL in 50% IPA/Hexanes

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	11.036	BB	0.6337	96.94768	2.25891	0.8775
2	36.663	MM	1.9852	5431.40820	45.59909	49.1628
3	40.457	MM	2.2358	5519.45410	41.14417	49.9597
Totals :				1.10478e4	89.00217	

Additional Info : Peak(s) manually integrated



Sample Info : CHIRALPAK OD-H
50% IPA
1.3 mg/mL in 50% IPA
0.110 mL/min
254 nm
5 uL inj.

Signal 1: VWD1 A, Wavelength=254 nm

Peak #	RetTime [min]	Type	Width [min]	Area [mAU*s]	Height [mAU]	Area %
1	36.522	MM	1.7919	2972.19873	27.64478	100.0000

Totals : 2972.19873 27.64478